Fig. 1: Longitudinal profiling of a clinically annotated GBM cohort.

a, Schematic representation describing the workflow of our study. TMZ, temozolomide; RT, radiotherapy; int., intermediate. b, Clinical and technical information on all 59 patients in this dataset, including surgical interval, age at diagnosis, gender, ___location at recurrence (rec), MGMT promoter status, therapy and omic data type. c, UMAP for dimension reduction based on gene expression values of the cells in our cohort colored according to the cell type (top) and time point (bottom). d, Proportion (%) of patients in the dataset in which a genetic aberration was detected, colored by time point. The donut chart at the top represents average somatic mutation distribution for whether an alteration was detected at both time points (T1 + T2), the primary tumor only (T1) or the recurrent tumor only (T2). The bar plot at the bottom is for the known driver genomic events and the representative phenotypes related to the genomic alterations—arm-level refers to whole chromosome arm amplification (amp) (chr7q)/deletion (del) (chr10q), CNA refers to high-level gene amplification or deletion, and SNV refers to single-nucleotide mutations. De novo hypermutation (HM) indicates a high mutation burden at both time points without evidence for treatment-associated mutational signatures. Small deletion indicates tumors with increased small deletion burden at recurrence. UMAP, uniform manifold approximation and projection; chr, chromosome; assoc., associated.